Lung Cancer Video Library Mandarin - Combinations of Immunotherapy Agents in Advanced NSCLC

Article and Video CATEGORIES

Cancer Journey

ABOUT

Dr. Jenny Jing Li is originally from China. She earned her undergraduate degree from Duke University where she majored in neuroscience and biology. She received her M.D. degree from Duke University School of Medicine and completed her Internal Medicine residency at University of Texas Southwestern Medical Center. She is currently undergoing her hematology/oncology fellowship training at Mayo Clinic in Rochester, MN

Lung Cancer Video Library Mandarin - Combinations of Immunotherapy Agents in Advanced NSCLC

dbrock

Tue, 01/29/2019 - 20:49

Lung Cancer Video Library - Mandarin

Author

Jenny J. Li, MD, GRACE Guest Faculty

Chinese Transcript-Combinations of Immunotherapy Agents in Advanced NSCLC Current Status.pdf

For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library.

In this video translation, Dr. Li discusses the current status of combinations of immunotherapy agents in advanced NSCLC.

We would like to thank the following sponsors:

Video Language

Mandarin

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.